Evidence map›Paper›PMID 42764300›Full record

ArticleNature communications2026

Targeting ABL kinases overcomes melanoma immune evasion following resistance to MAPK inhibition.

Rakshamani Tripathi, Bhuvanesh Sukhlal Kalal, Shirin Soni, Chezney Boothe, Anastasia Lyon, Christina Meeks, Daheng He, Phil Fang Cheng, Mitchell P Levesque, Jinpeng Liu and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Rakshamani TripathiDepartment of Pharmacology and Nutritional Sciences, University of Kentucky College of Medicine, Lexington, KY, USA.ORCID http://orcid.org/0000-0001-9394-1173
Bhuvanesh Sukhlal KalalDepartment of Pharmacology and Nutritional Sciences, University of Kentucky College of Medicine, Lexington, KY, USA.ORCID http://orcid.org/0000-0002-2560-3778
Shirin SoniDepartment of Pharmacology and Nutritional Sciences, University of Kentucky College of Medicine, Lexington, KY, USA.ORCID http://orcid.org/0009-0003-3764-7502
Chezney BootheDepartment of Pharmacology and Nutritional Sciences, University of Kentucky College of Medicine, Lexington, KY, USA.
Anastasia LyonDepartment of Pharmacology and Nutritional Sciences, University of Kentucky College of Medicine, Lexington, KY, USA.ORCID http://orcid.org/0000-0002-7365-4035
Christina MeeksDepartment of Pharmacology and Nutritional Sciences, University of Kentucky College of Medicine, Lexington, KY, USA.
Daheng HeBiostatistics and Bioinformatics Shared Resource Facility; Markey Cancer Center, University of Kentucky College of Medicine, Lexington, KY, USA.
Phil Fang ChengDepartment of Dermatology, University of Zurich Hospital and Faculty of Medicine, University of Zurich, Zurich, Switzerland.ORCID http://orcid.org/0000-0003-2940-006X
Mitchell P LevesqueDepartment of Dermatology, University of Zurich Hospital and Faculty of Medicine, University of Zurich, Zurich, Switzerland.ORCID http://orcid.org/0000-0001-5902-9420
Jinpeng LiuBiostatistics and Bioinformatics Shared Resource Facility; Markey Cancer Center, University of Kentucky College of Medicine, Lexington, KY, USA.
Chi WangBiostatistics and Bioinformatics Shared Resource Facility; Markey Cancer Center, University of Kentucky College of Medicine, Lexington, KY, USA.
Rina PlattnerDepartment of Pharmacology and Nutritional Sciences, University of Kentucky College of Medicine, Lexington, KY, USA. rplat2@uky.edu.ORCID http://orcid.org/0000-0002-9728-3224

Funding

University of Kentucky Markey Cancer Center Support Grant ECIA SupplementP30CA177558 · NCI · UNIVERSITY OF KENTUCKY · PI Jennifer F Rogers · 2013 to 2026
$38.3M
Combating melanoma resistance by targeting ABL1/2R01CA258751 · NCI · UNIVERSITY OF KENTUCKY · PI KOLESAR, JILL MARIE, PLATTNER, RINA · 2022 to 2025
$2.3M
NCI NIH HHS P30 CA177558NCI NIH HHS R01 CA258751U.S. Department of Health & Human Services | National Institutes of Health (NIH) P30 CA177558U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R01CA258751V Foundation for Cancer Research (V Foundation) T2025-009
6 · The paper itself

Abstract

MAPK inhibitors (MAPKi) are important treatment options for some patients with metastatic melanoma; however, resistance inevitably develops in the vast majority of cases (>70%). Here, using immune-proficient mouse models, single-cell RNA sequencing, flow cytometry, and datasets from patients treated with MAPKi, we demonstrate that ABL kinases (ABL1/2) promote MAPKi resistance not only by impacting intracellular signaling but also by driving secretion of chemokines that suppress the immune microenvironment. Targeting ABL1/2 reduces chemokine secretion by melanoma cells, prevents immunosuppressive myeloid-derived suppressor cell (MDSC) infiltration, and promotes accumulation of cytotoxic CD8

Indexed as

Drug Resistance, NeoplasmMelanomaProtein Kinase InhibitorsProto-Oncogene Proteins c-ablTumor EscapeAnimalsCD8-Positive T-LymphocytesCell Line, TumorChemokinesFemaleHumansMiceMice, Inbred C57BLMyeloid-Derived Suppressor CellsTumor MicroenvironmentABL1 protein, humanChemokinesProtein Kinase InhibitorsProto-Oncogene Proteins c-abl

Identifiers

PMID42764300
PMCPMC13590603

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.